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Dr John A. Kern (Charlottesville, Va). Thank you. I have noth-
ing to disclose.
Dr Gopaldas and his colleagues fromHouston have presented to
us the largest review to date of thoracic endovascular aneurysm
repair (TEVAR) versus open repair for isolated descending tho-
racic aortic aneurysms. This is a large database, and the results
were more or less as expected. These particular results square up
nicely with previously published reports, as you have pointed
out, and, in general, the lower surgical complications and lower
neurologic and respiratory complications should be looked on
favorably from a healthcare economics standpoint. Interestingly,
however, although the complications were lower in the TEVAR
patients, the procedure-related hospital stay and mortality was ac-
tually identical between the 2 groups. This is perhaps a little unex-
pected given the lower complications in the TEVAR group.
I would like to emphasize the study for what it is and what it is
not, and then I have 3 questions. First, the sheer number of patients
analyzed makes this study noteworthy, sample size is not an issue,
and TEVARwas proven safe and, indeed, perhaps superior to open
repair. In addition, this study represents a true broad snapshot, if
you will, of the real-world experience with the early widespread
adoption of what was at the time a new Food and Drug Adminis-1008 The Journal of Thoracic and Cardiovascular Surtration-approved technology, TEVAR, and it showed that it stood
up nicely to the reference standard, open repair. This is particularly
impressive when realizing that data was collected from more than
1000 hospitals nationwide, as you pointed out. Therefore, perhaps
the results are not too terribly skewed by the high-volume, experi-
enced academic referral centers where stent grafting technology
was developed, refined, and validated by the experts. Indeed, per-
haps some lower volume centers were included in this trial and
their data were analyzed, and this is good.
What is this study not? First, this study was not a prospective
randomized trial, and this study did not use propensity matching
to compare similar patients with subsequent outcomes. This study
did use an administrative database, which was probably very bare-
bones and, as you said, likely subject to coding errors and biases.
Although some patient demographics were collected—for exam-
ple, we saw that the TEVAR patients were older and perhaps
a bit sicker—we have no information concerning the actual nature,
pathology, location, extent, or size of the aneurysms treated. Thus,
it is possible that you were comparing apples and oranges. Second,
no information is known about the downstream subsequent conse-
quences after either TEVAR or open repair. This in fact is a partic-
ularly important feature of stent grafting, even more so now as we
tackle more complex and challenging aortic pathologic findings in
which type I endoleaks can be seen in as many as 20% of patients.
These situations obviously require significant downstream
resource use and expertise. The need for frequent reimaging and
reinterventions could make TEVAR a bit less attractive in the
long run for both patients and third-party payers. Although TE-
VAR might appear favorable compared with open repair during
the initial hospitalization, the cumulative cost and consequences
of subsequent hospitalizations and interventions are still unknown.
So I have 3 questions.
First, what do you hypothesize was the major mode of death in
the TEVAR group? Complications, specifically life-altering respi-
ratory and neurologic complications, appeared less frequently in
TEVAR, yet the mortality was similar. Is it possible the increased
mortality was related to the vascular access complications associ-
ated with the early adoption of TEVAR, and do you think these
vascular complications and mortality have improved in the 3
years?
DrGopaldas.Dr Kern, thank you for your very detailed perusal
of our manuscript and for your extremely valuable comments. My
first thing in response to your comment that we do not have infor-
mation on the follow-up, which is certainly a very valid point, one
thing that we do have to point out is that the routine discharge rates
were greater with TEVAR. Thus, an older patient was more likely
to go home, and, yes, come back for a reintervention, but then a pa-
tient of a similar age who had undergone open repair was probably
going to end up in a nursing home and stay there for a long time
and probably not go home. So, the critical issue here is we do
not have information on either of these, whether they go to a nurs-
ing home, how much it costs, or if they come back for reinterven-
tions for TEVAR procedures. That is certainly a limitation we
acknowledge.
In answer to your question about the mortality difference that
was not seen, which was actually interesting considering that
TEVAR independently predicted lower complications. To address
this, we analyzed our groups separately, TEVAR patients and opengery c November 2010
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Daortic repair. We conducted a regression model to determine what
actually were the predictors of mortality within these groups. Also,
I am going to point out 2 factors: one is intraoperative complica-
tions, the other is respiratory complications.
Now, TEVAR independently predicted a lower incidence of in-
traoperative complications; however, in the regression model sep-
arately, when an intraoperative complication occurred in the open
aortic repair group, it did not independently translate to mortality.
The odds ratio was 1.3, but the P value was not significant. In con-
trast, in a TEVAR patient, if they developed an intraoperative com-
plication, the P value was significant and the odds ratio was about
4.5. So what this tells us is TEVAR does decrease the incidence of
intraoperative complications, but when an intraoperative compli-
cation does occur in a TEVAR patient, it is more likely to result
in a grave consequence, such as death.
The same issue occurred with renal complications, because
TEVAR did not translate to any difference in renal complications,
but when we separately analyzed the 2 groups, a renal complica-
tion in an open aortic repair was associated with a 5 times risk
of mortality, but in a TEVAR patient, a renal complication was as-
sociated with a 12 times risk of mortality.
So what I think we are seeing here are 2 things: one is the effect
of TEVAR on the incidence of these complications and the second
is the failure to rescue. Also, I think when TEVAR patients develop
a complication, the failure to rescue from these complications by
either the surgical team or the hospital was higher, and, as a result,
they faced a greater mortality. I believe this is what seems to
compensate and balance out the advantages of TEVAR and thus
contributing to no overall difference.
To look at the other aspect, the length of stay was not different.
We do not have information on the postoperative length of stay. So
that is another limitation.
Dr Kern. That is a good analysis of those results.
Do you have any information from this database of the results
as they compare to high-volume or low-volume centers? These
data were captured when pretty straightforward aneurysms were
being treated. You can see how lower-volume centers can treat
that and do it well. We are starting to treat very complex aortic
pathologic features. So, based on whether you know the results
of low- versus high-volume centers, when it comes to very diffi-
cult dissections and disorders like that, should those still be treated
by everyone?The Journal of Thoracic and CarDrGopaldas. That is certainly a very valid question. One of the
factors we included in our analysis was hospital size, and that did
not seem to affect the outcome of these procedures, although I
must say this is an isolated descending thoracic aneurysm, which
is fairly straightforward. Also, these cases, if a community hospital
can do it well, it probably should be done there, rather than just
being referred to an aortic center. The primary care physician is
probably going to find a cardiologist or a vascular surgeon who
can just push a guide wire up higher into the arch and deploy these
stents, and these patients are not going to be knocking on the door
of cardiac surgeons. But then if you are looking at complex aortic
procedures, such as an arch in which extensive debranching is
required or a thoracoabdominal aneurysm, that is a separate issue.
For those patients, data are already available that have supported
that performing these complex procedures in high-volume centers
is justified. So for a straightforward isolated descending, I do not
think these patients need to be shunted to an aortic center per se,
but when it is complex requiring some debranching, absolutely,
I think.
DrHanni Shennib (Phoenix, Ariz). I enjoyed your presentation
very much, and it actually confirms a lot of the other meta-analyses
that were done more recently, including a publication in the
American Journal of Cardiology. The question I have to you is
a follow-up on your comment regarding intraoperative complica-
tions and that the risk and complication rate, including risk and
mortality, and what you quoted as rescue issues seems to be higher
in the TEVAR group than in the open group. Can you perhaps
retrieve information regarding who is billing for the procedure,
whether it is co-billed between a cardiologist or an interventional-
ist and a surgeon versus the whole operation being done by an
endovascular surgeon and perhaps come to some findings in regard
to the failure to rescue? How many of those procedures, the
TEVAR procedures, are done primarily by the endovascular
service (i.e., billed by the endovascular service) versus billed by
the cardiologist or interventional radiologist in the presence of
a surgeon?
Dr Gopaldas. That information, unfortunately, is not available
in this database. The Medicare database captures that in more de-
tail, but this database does have that limitation. It does not differ-
entiate between who is doing it. Whether a vascular surgeon or an
interventionalist or a cardiologist or a cardiac surgeon is doing the
procedure cannot be addressed with this database.diovascular Surgery c Volume 140, Number 5 1009
